Reduce tremor through brain stimulation
- Trial ID
- NCT06013956
- Official Title
- Identifying Circuit Dynamics Underlying Motor Dysfunction in Parkinson's Disease Using Real-Time Neural Control
- Goal
- Reduce tremor through brain stimulation
- Phase
- PHASE4
- Status
- RECRUITING
- Sponsor
- David Escobar
- Study Type
- INTERVENTIONAL
- Enrollment
- 25 participants
- Conditions
- Parkinson Disease
- Interventions
- Neurostimulation, Carbidopa 25/Levodopa 100Mg Tab
Plain-Language Summary
The goal is to pinpoint the specific brain circuit activity that causes tremor, slowness, and other motor problems in Parkinson's so stimulation can be timed and tuned to reduce those symptoms. The approach uses deep brain stimulation targeted to the subthalamic nucleus with real-time neural control, meaning the device watches brain signals and adjusts electrical stimulation on the fly, and researchers will test how that responsive stimulation works alongside carbidopa/levodopa, the standard medication that boosts brain dopamine to improve movement. Looking for adults 18 to 80 with idiopathic Parkinson's who have been cleared as candidates for STN-DBS, can give informed consent, and can tolerate brief delays in taking their Parkinson's meds; people with secondary parkinsonism, stroke, other progressive CNS diseases, or conditions that would interfere with safety or compliance are excluded.
Locations
- Cleveland Clinic, Cleveland, Ohio, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Neurostimulation. The goal is to pinpoint the specific brain circuit activity that causes tremor, slowness, and other motor problems in Parkinson's so stimulation can be timed and tuned to reduce those symptoms. The approach uses deep brain stimulation targeted to the subthalamic nucleus with real-time neural control, meaning the device watches brain signals and adjusts electrical stimulation on the fly, and researchers will test how that responsive stimulation works alongside carbidopa/levodopa, the standard medication that boosts brain dopamine to improve movement. Looking for adults 18 to 80 with idiopathic Parkinson's who have been cleared as candidates for STN-DBS, can give informed consent, and can tolerate brief delays in taking their Parkinson's meds; people with secondary parkinsonism, stroke, other progressive CNS diseases, or conditions that would interfere with safety or compliance are excluded.
- Who can participate?
- Participants must be between 18 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 4 trial is estimated to last approximately 4 years and 10 months.